ECSP12012083A - Pirrolidina-2-carboxamidas sustituidas - Google Patents

Pirrolidina-2-carboxamidas sustituidas

Info

Publication number
ECSP12012083A
ECSP12012083A ECSP12012083A ECSP12012083A EC SP12012083 A ECSP12012083 A EC SP12012083A EC SP12012083 A ECSP12012083 A EC SP12012083A EC SP12012083 A ECSP12012083 A EC SP12012083A
Authority
EC
Ecuador
Prior art keywords
pirrolidina
carboxamids
substituted
compounds
esters
Prior art date
Application number
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Xin Jie Chu
Qingjie Ding
Nan Jiang
Jin Jun Liu
Zhuming Zhang
Tina Morgan Ross
Jing Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP12012083A publication Critical patent/ECSP12012083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se proporcionan compuestos de la fórmula (consta gráfico) en la que X, Y, R1, R2, R3, R3, R4, R5, R6 y R7 tienen los significados aquí descritos y los enantiómeros y sales y ésteres farmacéuticamente aceptables de los mismos. Estos compuestos son útiles como agentes anticancerosos.
ECSP12012083 2010-02-09 2012-08-03 Pirrolidina-2-carboxamidas sustituidas ECSP12012083A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/702,402 US8354444B2 (en) 2008-09-18 2010-02-09 Substituted pyrrolidine-2-carboxamides

Publications (1)

Publication Number Publication Date
ECSP12012083A true ECSP12012083A (es) 2012-09-28

Family

ID=43608850

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012083 ECSP12012083A (es) 2010-02-09 2012-08-03 Pirrolidina-2-carboxamidas sustituidas

Country Status (32)

Country Link
US (1) US8354444B2 (es)
EP (1) EP2534132B1 (es)
JP (1) JP5612710B2 (es)
KR (1) KR101461298B1 (es)
CN (1) CN102753522B (es)
AR (2) AR080143A1 (es)
AU (1) AU2011214506C1 (es)
BR (1) BR112012019672B1 (es)
CA (1) CA2788236C (es)
CL (1) CL2012002189A1 (es)
CR (1) CR20120410A (es)
CY (1) CY1119049T1 (es)
DK (1) DK2534132T3 (es)
EC (1) ECSP12012083A (es)
ES (1) ES2629439T3 (es)
HK (1) HK1171452A1 (es)
HR (1) HRP20170903T1 (es)
HU (1) HUE034816T2 (es)
LT (1) LT2534132T (es)
MX (1) MX2012009186A (es)
MY (1) MY165238A (es)
NZ (1) NZ601422A (es)
PE (1) PE20121532A1 (es)
PL (1) PL2534132T3 (es)
PT (1) PT2534132T (es)
RS (1) RS56163B1 (es)
RU (1) RU2564022C2 (es)
SG (1) SG182763A1 (es)
SI (1) SI2534132T1 (es)
TW (1) TWI401243B (es)
UA (1) UA107954C2 (es)
WO (1) WO2011098398A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303676B2 (en) * 2003-02-13 2007-12-04 Zenon Technology Partnership Supported biofilm apparatus and process
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
HUE038714T2 (hu) 2011-03-10 2018-11-28 Daiichi Sankyo Co Ltd Dispiropirrolidin származék
EP2771008A4 (en) 2011-10-28 2015-04-08 Merck Sharp & Dohme MACROCYCLES INCREASING P53 ACTIVITY AND USES THEREOF
EP2793890B1 (en) 2011-12-21 2016-09-07 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8993614B2 (en) * 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20140200255A1 (en) * 2012-03-19 2014-07-17 Brian Higgins Method for administration
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
JP6067108B2 (ja) 2012-05-30 2017-01-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 置換ピロリジン−２−カルボキサミド
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2948141A1 (en) 2013-01-22 2015-12-02 F. Hoffmann-La Roche AG Pharmaceutical composition with improved bioavailability
EP2958893B1 (en) * 2013-02-21 2017-05-03 F. Hoffmann-La Roche AG Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
US20140275562A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto
WO2014202492A1 (en) * 2013-06-19 2014-12-24 F. Hoffmann-La Roche Ag Combination of ro5503781 and capecitabine for cancer therapy
PL3010508T3 (pl) * 2013-06-19 2019-12-31 F. Hoffmann-La Roche Ag Skojarzenie RO5503781, kapecytabiny i oksaliplatyny do leczenia raka
BR112015029976A2 (pt) * 2013-06-24 2017-07-25 Hoffmann La Roche formulação farmacêutica, formulação liofilizada farmacêutica e preparações novas, métodos e usos
AU2014286237B2 (en) 2013-07-03 2020-08-20 F. Hoffmann-La Roche Ag mRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
SG11201604504VA (en) 2013-12-05 2016-07-28 Hoffmann La Roche Novel combination treatment for acute myeloid leukemia (aml)
US9657351B2 (en) 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist
JP6621761B2 (ja) * 2014-04-15 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 薬学的に活性な化合物の固体形態
SG10201913742TA (en) 2014-04-17 2020-03-30 Univ Michigan Regents Mdm2 inhibitors and therapeutic methods using the same
JP6162646B2 (ja) * 2014-05-27 2017-07-12 信越化学工業株式会社 ３，５−ジメチルドデカン酸の製造方法
CN106716131B (zh) * 2014-10-10 2020-07-24 豪夫迈·罗氏有限公司 Mdm2拮抗剂的癌症疗法的患者个性化方法
NZ736450A (en) * 2015-03-30 2022-04-29 Mission Therapeutics Ltd 1-cyano-pyrrolidine compounds as usp30 inhibitors
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
KR102122469B1 (ko) 2016-11-01 2020-06-12 주식회사 엘지화학 변성 공액디엔계 중합체 및 이의 제조방법
WO2018120094A1 (zh) 2016-12-30 2018-07-05 泸州东方农化有限公司 一种制备2-(亚环己烯基)丙二酸衍生物的方法及其应用
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
BR112020000553A2 (pt) 2017-07-11 2020-07-21 Vertex Pharmaceuticals Incorporated carboxamidas como moduladores de canal de sódio
CN108586195A (zh) * 2017-12-27 2018-09-28 北京汇康博源医药科技有限公司 一种5-羟基-7，7-二甲基-2h-茚酮的制备方法
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
JP2023504546A (ja) 2019-12-06 2023-02-03 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての置換テトラヒドロフラン
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN116459225B (zh) * 2023-04-26 2023-11-10 东莞市金美济药业有限公司 一种艾拉戈克钠片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732902A (en) 1986-05-23 1988-03-22 Hoffmann-La Roche Inc. Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
WO1999011606A2 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
US7759383B2 (en) * 2005-02-22 2010-07-20 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
KR100944301B1 (ko) 2005-02-22 2010-02-24 더 리젠츠 오브 더 유니버시티 오브 미시간 Ｍｄｍ２의 소분자 억제제 및 이의 용도
CA2610428A1 (en) 2005-06-17 2006-12-21 Astrazeneca Ab Thrombin inhibiting 2-oxo-1, 2, 5, 6-tetrahydropyridine derivatives
KR20090042779A (ko) 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
RU2459619C2 (ru) 2006-12-06 2012-08-27 Санофи-Авентис Мочевина и сульфамидные производные в качестве ингибиторов tafia
TW200911787A (en) 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8134001B2 (en) * 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
JP5531011B2 (ja) 2008-06-06 2014-06-25 サノフイ ＴＡＦＩａの阻害剤としての大環状尿素およびスルファミド誘導体
EA018502B1 (ru) 2008-06-23 2013-08-30 Астразенека Аб Новые гетероциклические карбоксамиды и фармацевтические композиции, содержащие их
GB0811643D0 (en) * 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions

Also Published As

Publication number Publication date
RS56163B1 (sr) 2017-11-30
EP2534132A1 (en) 2012-12-19
DK2534132T3 (en) 2017-07-10
MY165238A (en) 2018-03-14
TWI401243B (zh) 2013-07-11
TW201136892A (en) 2011-11-01
AU2011214506C1 (en) 2014-07-17
AU2011214506B2 (en) 2014-04-17
HRP20170903T1 (hr) 2017-09-08
AU2011214506A1 (en) 2012-08-16
CN102753522A (zh) 2012-10-24
CY1119049T1 (el) 2018-01-10
PT2534132T (pt) 2017-06-26
LT2534132T (lt) 2017-07-10
WO2011098398A1 (en) 2011-08-18
BR112012019672A2 (pt) 2016-05-03
ES2629439T3 (es) 2017-08-09
EP2534132B1 (en) 2017-04-26
JP5612710B2 (ja) 2014-10-22
CA2788236C (en) 2015-01-20
KR101461298B1 (ko) 2014-11-28
RU2012138257A (ru) 2014-03-20
CN102753522B (zh) 2013-11-27
PL2534132T3 (pl) 2017-09-29
AR080143A1 (es) 2012-03-14
HUE034816T2 (en) 2018-02-28
RU2564022C2 (ru) 2015-09-27
US20100152190A1 (en) 2010-06-17
HK1171452A1 (en) 2013-03-28
JP2013518921A (ja) 2013-05-23
CR20120410A (es) 2012-09-05
PE20121532A1 (es) 2012-11-26
UA107954C2 (en) 2015-03-10
NZ601422A (en) 2014-07-25
SG182763A1 (en) 2012-08-30
CL2012002189A1 (es) 2012-11-23
SI2534132T1 (sl) 2017-08-31
MX2012009186A (es) 2012-08-23
US8354444B2 (en) 2013-01-15
CA2788236A1 (en) 2011-08-18
AR114159A2 (es) 2020-07-29
BR112012019672B1 (pt) 2020-11-17
KR20120119922A (ko) 2012-10-31

Similar Documents

Publication Publication Date Title
ECSP12012083A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP11010898A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP12011945A (es) Espiroindolinona-pirrolidinas
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
ECSP12011625A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
DOP2014000152A (es) Inhibidores de bromodominios
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
CR20150250A (es) Nuevos derivados de piridina
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
IN2012DN02487A (es)
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20130239A (es) Compuestos de triazolopiridina
NI201100096A (es) Lactamas como inhibidores de beta secretasa.
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
CR11759A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CR20110387A (es) Microbiocidas nuevos
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico